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Abstract  
 
The prognosis of breast cancer patients is closely associated with the response of 
tumor cells to chemotherapy agent. Doxorubicin is one of the primary chemotherapeutic 
agents used for the treatment of breast cancer. Resistance to chemotherapy is believed to 
cause treatment failure in cancer patients. Furthermore, long time exposure to 
chemotherapeutic agent induces cancer cells resistance. MCF-7 sensitive cells used as 
chemoresistance model have overexpression P-gp (P-glycoprotein). Chemoresistance was 
established by treating MCF-7 cells with 0.5 µg/ml doxorubicin-contained medium for a week. 
50% inhibiting concentration (IC50) doxorubicin on MCF-7 cells/DOX were determined using 
MTT assay. Western blot assay and immunocytochemistry assay was performed to determine 
the expression of P-gp. Morphological of MCF-7 cell/DOX was changing to become larger and 
have lamellapodia. IC50 value of doxorubicin was 700 nM on MCF-7/DOX and 400 nM on 
sensitive MCF-7 cells. The MCF-7/DOX sensitivity to doxorubicin was decreased, shown by 
1.5 fold higher IC50 of doxorubicin on MCF-7/DOX compared to MCF-7 sensitive cells. 
Treatment doxorubicin to sensitive MCF-7 cells leads to the increasing P-gp expression. The 
P-gp level expression has strong correlation with the low sensitivity of MCF-7/DOX to 
doxorubicin. 
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INTRODUCTION  
 
Protein transporter, such as P-glycoprotein 
plays a pivotal role in developing of cancer cells 
resistance. The ABC (ATP Binding Cassete) 
superfamily includes ± 300 protein as transporters 
of different compound. Protein of ABC family is a 
type of adenosine triphosphatase (ATPase) and an 
energy-dependent trans membrane drug efflux (Loo 
et al., 2005). These ABC family includes The ABC 
family ± 300 protein as transporters of different 
compound (Higgins, 2007) and divided into 7 sub 
families (Dean, 2001). One of them is MDR (Multi 
Drug Resistance). P-glycoprotein (P-gp) is a 
identified ATP-binding cassette transporter, 
correlated to multidrug resistant (MDR-1) gene 
expression (Varma et al., 2003), and shown to be 
an important anticancer agents and play an 
important function in governing drug disposition 
(Gottesman et al, 2001). P-gp effluxes 
chemotherapeutic agent extracellular via ATP 
hydrolysis 
Doxorubicin, a chemotherapeutic agent 
frequently used for the treatment of several cancers, 
is widely used for the treatment of breast cancer. 
However, long treatment of doxorubicin induces 
cardiotoxicity and cancer resistance (Gandhi et al., 
2007). Doxorubicin is a P-gp substrate (Coley, 
2009). Doxorubin is effluxed by P-gp (Michor et 
al., 2006), resulting in decrease concentration of 
doxorubicin intracellular. This mechanism 
mediates the cancer cell resistance to doxorubicin.  
This study was aimed to develop MCF-7 
breast cancer cell line resistant to doxorubicin 
(MCF-7/DOX). The result, then, will be used in 
researches to develop chemopreventive agent 
targeting resistant cells. Thus, we need to 
determine the characteristic of MCF-7/DOX 
resulted from this study. 
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MATERIALS AND METHODS 
 
Chemicals 
Doxorubicin (10mg/5 ml, Ebewe), universal 
detection kit (streptavidin-HRP, second antibody 
biotinilasi, horse radish serum/blocking serum) 
(Ultravision plus detection system, Ref TP 125-
HLX, Runcorn, Cheshire, WA71PR, UK; 
Novostain Universal Detection kit NCL-RTU, 
Novocastra Lab Ltd., Newcastle NE12 8EW, UK). 
 
Cell Lines and drug treatment 
MCF-7 cells were obtained from the 
collection of Cancer Chemoprevention Research 
Center (CCRC), Faculty of Pharmacy, Universitas 
Gadjah Mada. The cell line was kindly gift from 
Prof. Kawaichi, Nara Institute of Science and 
Technology (NAIST), Japan. The resistant cells 
were originated by growing initial MCF-7 cells 
with doxorubicin concentration of 0.5 µg/ml. 
Doxorubicin was added every day for a week. 
Then, the cells were maintained with 0.1 µg/ml 
doxorubicin and fresh medium alternately. Check 
the IC50 to ensure that the resistancy. MCF-7 
sensitive cells and MCF-7/DOX cells were grown 
in suspension using Dulbecco’s Modified Eagle 
Medium (DMEM) medium (Gibco) supplemented 
with 10% Fetal Bovine Serum (FBS) (Gibco), 
10,000 units/ml penicillin-10,000 μg/ml 
streptomycin (Gibco) at 37
0
C in humidified 5% 
CO2.  
 
Cytotoxicity assay  
MTT cytotoxicity assay was used to 
examine the effect of doxorubicin on MCF-7 
sensitive cells and MCF-7/DOX cells. MCF-7 
sensitive cells and MCF-7/DOX cells were 
distributed into 96-well plate with the density of 
1x10
4
 cells/well, then were incubated in 37˚C with 
5% CO2 for 24 hours. Doxorubicin was applied 
with the concentration of 1, 10, 50, 100, 250, 500, 
and 1.000 nM. After 24 hours incubation, culture 
medium was removed followed by PBS washing. 
Then, 3-[4,5-dimethyl thiazole-2-yl(-2,5- 
diphenyltetrazoliumbromide)] (MTT) 0.5 mg/ml in 
PBS was applied, followed by 4 hours incubation 
in 37˚C with 5% CO2. SDS 10%
v
/v in HCl 0.01N as 
stopper reagent was then applied. Plate was then 
kept with protection from light overnight, 
continued with absorbance determination (λ 595 
nm) using ELISA reader (Bio-Rad). 
 
Western blot 
 
Cells were harvested, washed with PBS, and 
lysate for 30 minutes on ice using lysis buffer 
(20nM Tris HCl, pH 8.0, 5nM EDTA, 1%NP 40, 
25 mM NaCl and complete inhibitors of protease. 
The protein concentration was determined using 
Bradford assay. After electrophoresis, the proteun 
was transferred to PVDV membrane. The PVDV 
membrane was blocked with 5 % skim milk in PBS 
at room temperature for 1 hour. The membrane 
then washed with PBS, and incubated with 
antibody monoclonal purified mouse anti-human 
anti-Pgp (AbCam) 1:50 for 1 hour, the levels of 
protein were analyzed by enhanced 
chemiluminescene with an ECL plus Western 
blotting detection (Amersham, USA). 
 
Immunocytochemistry 
Coverslips (Iwaki) were placed in 24-well 
plate (Iwaki). Then MCF-7 sensitive cells and 
MCF-7/DOX were seeded (5x10
4
 cells/well). After 
24 hours incubation, cells were treated with 
doxorubicin for 18 h. Culture medium was 
removed and cells were washed in PBS, fixed using 
cold methanol and added with H2O2 blocking 
solution. Cells were added with prediluted blocking 
and incubated with monoclonal antibody 
monoclonal purified mouse anti-human anti-Pgp 
(AbCam) 1:100 overnight. Then, cells incubated 
with biotinylated universal secondary antibody, 
streptavidin-peroxidase and stained with substrate 
solution DAB. Cells were counterstained with 
Mayer Haematoxylin. Coverslips, then, were fixed 
with ethanol and xylol and moved onto object-
glass. After that, mounting media were added and 
coverslips were covered by other coverslips. 
Protein expression was observed using light 
microscope (Nikon YS100). Cells with positive P-
gp expression appear in brown/dark color, while 
cells with negative protein expression appear in 
blue/violet color. Immunocytochemistry analysis 
used provided evidence for localization of P-gp.  
 
Analysis  
Cytotoxicity assay Linear regression 
between concentration and percentage of cell 
viability giving the equation y = Bx + A were used 
to calculate IC50 value, the concentration that 
inhibits 50% cell proliferation.  
Statistical analysis. Statistical analysis was done 
using SPSS 16 software. T-test was used to 
evaluate the significance of the differences between 
groups. p>0.05 was considered as the significant 
difference. 
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RESULTS AND DISCUSSION 
 
Morphological on MCF-7/DOX 
Doxorubicin with concentration of 0.5µg/ml 
exposed to MCF-7 sensitive cells for a week lead to 
morphological changing (Fig. 1). The MCF-7/DOX 
cells were found to be larger than MCF-7 sensitive 
cells. It was also observed that MCF-7/DOX have a 
lamellapodia and filopodia. The MCF-7/DOX cells 
were attached tightly to the surface compared to 
MCF-7 sensitive cells. 
 
Doxorubicin–induced resistant on MCF-7 
sensitive cells. 
Cancer cell resistant to chemotherapeutic 
agent was signed to reduce sensitivity. The 
alteration of doxorubicin sensitivity on MCF-
7/DOX cells, exposed to doxorubicin in sub toxic 
concentration for a week, was compared to MCF-7 
sensitive cells. The cell viability was determined by 
MTT assay. IC50 value of doxorubicin on sensitive 
MCF-7 cells and MCF-7/DOX cells were 400 nM 
and 700 nM, respectively (Fig. 2). The sensitivity 
of MCF-7/DOX to doxorubicin were decrease to 
1.5 fold compared to MCF-7 sensitive cells.  
 
Expression of P-gp on MCF-7 sensitive cells 
and MCF-7/DOX 
 To clarify whether the induction of P-gp 
expression on MCF-7 cells resistance by 
doxorubicin 0.5 µg/ml for a week, an western blot 
assay for whole protein samples extracted from 
MCF-7 sensitive cells and MCF-7/DOX cells was 
carried out. As shown in Fig. 3, treated by 
doxorubicin increased level of P-gp. On MCF-
7/DOX cells showed higher expression of P-gp 
than MCF-7 sensitive cells.  
MCF-7 sensitive cells expressed relatively 
undetected Pgp, while MCF-7/DOX were 
obviously overexpressed Pgp in their cell 
membrane. All these results, level expression of P-
gp and site of P-gp in membran cells, corelation 
with decreasing sensitivity of doxorubicin on MCF-
7/DOX. 
 
 
  
 
  
 
 
Figure 1.   MCF-7 sensitive cells (A) and MCF-7/DOX (B) cells’ morphology (300x magnifications). This 
phenomenon showed morphological changes on MCF-7/DOX after doxorubicin exposure for a 
week. 
 
 
(A) (B) 
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Figure 2.  The cytotoxic effect of doxorubicin on MCF-7 sensitive cells and MCF-7/DOX cells, showing a 
reduce sensitivity of doxorubicin on MCF-7/DOX cells. Giving IC50 value of 400 nM on MCF-7 
sensitive and 700 nM on MCF-7/DOX cells. 
 
 
  
 
 
                                             MCF-7           MCF-7 
                                                      Sensitif           /DOX 
Figure 3. The effect of expression of P-gp by doxorubicin exposure 0.5 µg/ml doxorubicin for a week on 
MCF-7 sensitive cells. Doxorubicin induce expression of P-gp was detected by western blotting on 
MCF-7/DOX. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                     
 P-gp (140 KDa) 
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Figure 3.  Doxorubicin exposure for a week increased P-gp expression on MCF-7/DOX cells compared to 
MCF-7 sensitive cells. Sensitive MCF-7 and MCF-7/DOX cells (5x104 cells/well) were plated on coverslips in 
24-well plate and 24 h after plating, the cells were treated with agents for 20 h. (A). MCF-7 sensitive cells 
without staining antibody anti P-gp,(B). MCF-7 sensitive cells staining antibody anti P-gp (C). MCF-7/DOX cells 
without staining antibody anti P-gp, (D). MCF-7/DOX cells staining anti P-gp. Original magnification was 400x. 
Cells expressed P-gp showed brown color in membrane. 
 
Prolonged exposure of chemotherapeutic 
agent on cancer cells leads to decreased sensitivity 
to it. This research was conducted to develop 
doxorubicin resistance MCF-7 (MCF-7/DOX). The 
results, then, will be used in other research to 
develop chemoprevention agents that target 
resistant cells. Thus, we need to determine the 
characteristic of MCF-7/DOX resulted from this 
study. 
After treatment with doxorubicin as 
mentioned in material and methods, MCF-7/DOX 
sensitivity to doxorubicin were decreased. MCF-
7/DOX were 1.5 fold more resistant to the 
cytotoxic effect of doxorubicin compared to MCF-
7 sensitive cells. The sensitivity of MCF-7/DOX to 
doxorubicin was lower than of MCF-7/DOX 
developed by Lukyanova et al. (2009). Lukyanova 
et al. (2009) was successes in developing 16 fold 
resistant to doxorubicin compared to the initial 
MCF-7 cells. This difference may be due to the 
method divergence in resistance development. 
Lukyanova et al., (2009) induced MCF-7 resistant 
cells using doxorubicin with 0.1 to 32 μg/ml 
doxorubicin and test the IC50 every two months 
value until cells were 16 fold more resistant to the 
cytotoxic effect doxorubicin as compared with the 
initial MCF-7 cells, while we only used 0.5 μg/ml 
doxorubicin for a week. Thus, the sensitivity of 
MCF-7/DOX developed in this study was different 
to MCF-7/DOX developed by Lukyanova et al. 
MCF-7/DOX cells were strongly attached to 
the underlying substrate, as described by 
Lukyanova et al. (2009). The strongly adhesion 
might be caused by overexpression of the number 
of microtubules. Besides the strong attachment to 
the substrate, MCF-7/DOX cells showed to have 
bigger lamellapodia and filopodia compared to the 
MCF-7 sensitive cells. These changes were also 
observed by Lukyanova et al. (2009). The 
morphological changes on MCF-7/DOX are 
probably due to the Rac-1 activity. Rac-1 induces 
the lamellapodia and filopodia formation compiling 
the cell cytoskeleton. Acivation of Rac-1 in 
response to extracellular signaling will lead to Pak1 
acitvation. Pak1 phosphorylates the myosin light 
chain, protein involved in cell motility. Pak1 also 
depolymerizes F-actin through LIM kinase and 
cofilin (Yang et al., 1998), resulting in lamellipodia 
and filopodia outgrowth. Ruffling lamellopodia is 
associated with the creation of new substrate 
contact (Rottner et al., 1999), resulting in stronger 
adhesion to the underlying surface (Lukyanova et 
al., 2009). These possibilities should be explored 
more. 
The level of Pgp overexpression was 
confirmed by western blot assay. The MCF-7/DOX 
gave higher level of P-gp expression than MCF-7 
sensitive cells. This finding indicated that treatment 
0.5 µg/ml doxorubicin for a week induce P-gp 
overexpression. P-gp is an intergral plasma 
membrane protein and to be a major contributor to 
drug resistance (Kano et al., 2011). And based on 
immunocytochemisty assay, P-gp has been 
localized in membrane cells to do its fuction as 
substrate transporter. The Western blot and 
immunocytochemisty’ results were correlated with 
IC50 value of doxorubicin on MCF-7/DOX. That 
mean, treatement doxorubicin 0.5 µg/ml for a week 
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can be used as breast cancer resistant to 
doxorubicin. Further study on resistant induction of 
doxorubicin and localization P-gp on plasma 
membrane need to be conducted in order to know 
more about its molecular mechanism. 
 
CONCLUSION  
 
From this study, exposure of doxorubicin 0.5 
µg/ml (sub toxic concentration) for a week 
enhances P-gp expression correlated with the low 
sensitivity of doxorubicin on MCF-7/DOX. 
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